In 2017, PSMA PET is able to detect >50% of PSMA positive lymph nodes with a short axis diameter <8mm. When comparing 18F-fluoromethylcholine and 68Ga-PSMA at various PSA levels, the head-to-head detection level at various cut-points favors 68Ga-PSMA: PSA <0.5 ng/mL – 50% vs 12.5%; PSA 0.5-2.0 ng/mL – 71% vs 36%; PSA >2.0 ng/mL – 88% vs 63% . However, as Dr. Haberkorn notes, even though 68Ga-PSMA PET outperforms conventional CT imaging for detection of lymph node metastases, what do we do when planning for IMRT regarding the lesions that we don’t see? Importantly, if 68Ga-PSMA PET increases detection of lesions, does it change treatment planning? In a small study assessing primary prostate cancer recurrences (n=44; n=15 initial diagnoses), 63% of patients had overall management changed after 68Ga-PSMA PET imaging .
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Speaker: Uwe Haberkorn, University Hospital Heidelberg and DKFZ Heidelberg, Heidelberg, Germany
Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, Twitter: @zklaassen_md at the European Society for Medical Oncology Annual Congress - September 8 - 12, 2017 - Madrid, Spain
1. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-Fluromethylcholine versus 68GA-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56(8):1185-1190.
2. Cardinale J, Schafer M, Benesova M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med 2017;58(3):425-431.